Saroglitazar ( DrugBank: Saroglitazar )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
93	Primary biliary cholangitis	2

93. Primary biliary cholangitis

---

Clinical trials : 282 /  Drugs : 245 - (DrugBank : 56) / Drug target genes : 35 - Drug target pathways : 113

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05133336 (ClinicalTrials.gov)	March 15, 2022	1/11/2021	Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis	A Multicenter, Randomized, Double-blind, Placebo Controlled, Phase 2b/3 Study to Evaluate the Efficacy and Safety of Saroglitazar Magnesium in Subjects With Primary Biliary Cholangitis	Primary Biliary Cholangitis	Drug: Saroglitazar Magnesium 1 mg;Drug: Saroglitazar Magnesium 2 mg;Drug: Placebo	Zydus Therapeutics Inc.	NULL	Not yet recruiting	18 Years	75 Years	All	192	Phase 2/Phase 3	NULL
2	NCT03112681 (ClinicalTrials.gov)	August 18, 2017	10/4/2017	Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Mg in Patients With Primary Biliary Cholangitis	A Phase 2, Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Magnesium in Patients With Primary Biliary Cholangitis (EPICS )	Primary Biliary Cirrhosis	Drug: Saroglitazar magnesium 2 mg;Drug: Saroglitazar magnesium 4 mg;Drug: Placebo Oral Tablet	Zydus Discovery DMCC	NULL	Active, not recruiting	18 Years	75 Years	All	37	Phase 2	United States